Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen raises guidance, discontinues CETP inhibitor

In its 3Q17 earnings late Wednesday, Amgen Inc. (NASDAQ:AMGN) bumped up its 2017 guidance and said it discontinued internal development of

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE